Marinus Pharmaceuticals Statistics Share Statistics Marinus Pharmaceuticals has 55.22M
shares outstanding. The number of shares has increased by 0.24%
in one year.
Shares Outstanding 55.22M Shares Change (YoY) 0.24% Shares Change (QoQ) 0% Owned by Institutions (%) 72.28% Shares Floating 37.39M Failed to Deliver (FTD) Shares 61,426 FTD / Avg. Volume 3.39%
Short Selling Information The latest short interest is 2.18M, so 3.95% of the outstanding
shares have been sold short.
Short Interest 2.18M Short % of Shares Out 3.95% Short % of Float 3.96% Short Ratio (days to cover) 1.44
Valuation Ratios The PE ratio is -1.03 and the forward
PE ratio is -2.62.
Marinus Pharmaceuticals's PEG ratio is
0.
PE Ratio -1.03 Forward PE -2.62 PS Ratio 4.72 Forward PS 0.5 PB Ratio 8.72 P/FCF Ratio -1.24 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Marinus Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.07,
with a Debt / Equity ratio of 6.58.
Current Ratio 4.07 Quick Ratio 4.01 Debt / Equity 6.58 Debt / EBITDA -0.88 Debt / FCF -0.93 Interest Coverage -7.78
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $187.81K Profits Per Employee $-857K Employee Count 165 Asset Turnover 0.18 Inventory Turnover 0.8
Taxes Income Tax -1.54M Effective Tax Rate 1.08%
Stock Price Statistics The stock price has increased by -60.43% in the
last 52 weeks. The beta is 1.26, so Marinus Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.26 52-Week Price Change -60.43% 50-Day Moving Average 0.43 200-Day Moving Average 1.06 Relative Strength Index (RSI) 70.4 Average Volume (20 Days) 1,810,773
Income Statement In the last 12 months, Marinus Pharmaceuticals had revenue of 30.99M
and earned -141.41M
in profits. Earnings per share was -2.63.
Revenue 30.99M Gross Profit 29.05M Operating Income -131.49M Net Income -141.41M EBITDA -125.5M EBIT -126.05M Earnings Per Share (EPS) -2.63
Full Income Statement Balance Sheet The company has 120.57M in cash and 110.36M in
debt, giving a net cash position of 10.21M.
Cash & Cash Equivalents 120.57M Total Debt 110.36M Net Cash 10.21M Retained Earnings -571.93M Total Assets 63.62M Working Capital 22.9M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -118M
and capital expenditures -119K, giving a free cash flow of -118.12M.
Operating Cash Flow -118M Capital Expenditures -119K Free Cash Flow -118.12M FCF Per Share -2.2
Full Cash Flow Statement Margins Gross margin is 93.76%, with operating and profit margins of -424.3% and -456.31%.
Gross Margin 93.76% Operating Margin -424.3% Pretax Margin -461.27% Profit Margin -456.31% EBITDA Margin -404.97% EBIT Margin -424.3% FCF Margin -381.17%
Dividends & Yields MRNS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for MRNS is $3,
which is 445.5% higher than the current price. The consensus rating is "Hold".
Price Target $3 Price Target Difference 445.5% Analyst Consensus Hold Analyst Count 8
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 23, 2020. It was a
backward
split with a ratio of 1:4.
Last Split Date Sep 23, 2020 Split Type backward Split Ratio 1:4
Scores Altman Z-Score -20.13 Piotroski F-Score 3
